Furthermore, a train of evidence indicates that PRDX1 and other ROS‐regulated enzymes are targets for modulating intracellular redox status in therapeutic strategies for prostate cancer 109, 110, 111. The gene discussed is PRDX1; the disease is prostate carcinoma.